人工心臓市場：タイプ、技術、エンドユーザー、地域別、2026年～2032年

人工心臓市場の評価、2026年～2032年

人工心臓の需要は、主に心血管障害の世界の頻度の上昇に起因して急速に拡大しています。心不全は、冠動脈疾患、高血圧、心臓発作などの病気によって引き起こされることが多く、世界人口の高齢化と生活習慣に関連した健康問題の増加に伴い、ますます広まっています。残念なことに、移植用のドナー心臓の供給は限られており、その結果、臓器を必要とする人々の数と利用可能な臓器の数にかなりの格差が生じています。このため、2024年には25億9,000万米ドルの売上を超え、2032年には約73億4,000万米ドルの評価額に達する見込みです。

技術の躍進も人工心臓の需要拡大に大きく貢献しています。材料科学、小型化、生体適合性の進歩は、自然の心臓活動をよりよく再現できる、より洗練された人工心臓への道を開いています。こうした技術革新は、問題を最小限に抑え、装置の寿命を延ばすことで患者の生活の質を向上させ、2026年から2032年までのCAGR 13.92%での市場の成長を可能にしています。

人工心臓市場定義/概要

人工心臓は、一時的または永続的に、機能不全に陥った人間の心臓の代わりとなり、血液の流れや酸素の体内への供給を維持する機械装置です。人工心臓は主に、心臓が血液を効率的に送り出すことができなくなった末期心不全などの重篤な心臓疾患を持つ患者に使用されます。人工心臓は、循環系を通して血液を送り出すことにより、自然の心臓の機能を再現し、重要な臓器が機能するのに必要な酸素と栄養を確実に供給します。

人工心臓は、機能不全に陥った人間の心臓の機能を代替する画期的な医療機器であり、重篤な心疾患を患う患者に救命のサポートを提供します。人工心臓の重要な用途のひとつは、心臓移植への橋渡しです。人工心臓は、心臓が血液を十分に送り出すことができなくなった末期心不全の患者に対して、一時的に機能不全の臓器の代わりをすることができます。これにより、患者は移植用のドナー心臓を待つ間、生き延びることができます。

機械心臓の将来的な使用は、重篤な心疾患を持つ患者に新たな希望を与え、循環器学を変える可能性を秘めています。心臓病の世界の負担が増加するにつれ、ドナーの臓器がないなどの医学的理由で心臓移植を受けられない患者にとって、人工心臓はますます重要な選択肢となってきています。これらの人工心臓は、血液を全身に送り出し、心臓の機能を長持ちさせる、天然の心臓と同様の働きをするように設計されています。

患者自身の心臓が機能しなくなっても、血液を全身に送り、延命できるように設計されています。

心血管疾患の発生率増加は人工心臓市場を牽引するか？

心血管疾患（CVD）の発生率の増加は、人工心臓市場の主要な促進要因です。世界保健機関（WHO）によると、心血管疾患は世界の死亡原因の第一位であり、毎年推定1,790万人が死亡しています。これは世界全体の死因の31％を占める。CVDの有病率は継続的に増加しており、特に中低所得国ではCVDによる死亡の75％以上を占めています。米国だけでも、疾病対策予防センター（CDC）によれば、心臓病は年間約65万5,000人（死亡者の4人に1人）を占める主要な死因です。

このCVD有病率の憂慮すべき上昇は、末期心不全患者の救命治療としての人工心臓の需要を増大させると予測されています。米国国立心肺血液研究所（NHLBI）の推計によると、米国の成人の心不全患者は約620万人で、この数字は2030年までに800万人以上に増加すると予測されています。さらに、米国臓器分与ネットワーク（UNOS）の報告によると、2021年現在、米国では3,500人以上が心臓移植の待機リストに名を連ねています。ドナー心臓の不足が続いていることから、人工心臓は移植までの重要な橋渡しの選択肢、あるいは状況によっては目的地療法としての役割を果たします。

高コストは人工心臓市場の妨げになるか？

人工心臓の高コストは市場拡大の大きな障壁となり、普及とアクセシビリティを制限する可能性があります。米国立衛生研究所（NIH）によれば、人工心臓移植にかかる費用は、装置と関連医療を含めて全体で15万～50万米ドルに及ぶ。多くの患者やヘルスケアシステム、特に発展途上国や医療資源の乏しい地域では、経済的負担が大きいため、人工心臓を購入する余裕がないです。メディケア・メディケイド・サービスセンター（CMS）によると、対象となる受給者には特定の補助人工心臓（VAD）が適用されるもの、完全な人工心臓移植には通常保険が適用されないため、このような手術を頻繁に必要とする高齢患者の利用はさらに制限されます。

高額な費用は、患者へのアクセスだけでなく、この分野の研究開発にも影響を及ぼしています。食品医薬品局（FDA）は、人工心臓の承認に必要な長期の臨床試験には数億米ドルのコストがかかるため、一部の企業は市場への参入や斬新なデザインの開発を控えていると主張しています。このような高額な参入障壁は、技術開発を阻害し、競争を妨げ、長期的には高コストを維持する可能性があります。さらに、国立心肺血液研究所（NHLBI）は、人工心臓研究のための政府資金は近年増加しているもの、この分野における急速な技術革新とコスト削減を促すにはまだ不十分であると述べています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 人工心臓市場：タイプ別

• 全人工心臓（TAH）
• 左室補助人工心臓（LVAD）

第5章 人工心臓市場：技術別

• 常用流技術
• 拍動流技術

第6章 人工心臓市場：エンドユーザー別

• 病院
• 外来手術センター（ASCs）

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• SynCardia Systems, LLC
• Carmat
• Abiomed
• CryoLife, Inc.
• ReinHeart TAH GmbH
• Jarvik Heart, Inc.
• Calon Cardio-Technology Ltd.
• BiVACOR, Inc.
• CARMAT SA
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Artificial Heart Market Valuation - 2026-2032

The demand for artificial hearts is quickly expanding owing mostly to the rising global frequency of cardiovascular disorders. Heart failure which is frequently caused by illnesses such as coronary artery disease, high blood pressure, and heart attacks is growing increasingly widespread as the world's population ages and lifestyle-related health issues increase. Unfortunately, the supply of donor hearts for transplantation is limited resulting in a considerable disparity between the number of people in need and the organs available by enabling the market to surpass a revenue of USD 2.59 Billion valued in 2024 and reach a valuation of around USD 7.34 Billion by 2032.

Technological breakthroughs are also contributing significantly to the growing demand for artificial hearts. Materials science, downsizing, and biocompatibility advancements are paving the way for more sophisticated artificial hearts that can better replicate natural cardiac activities. These innovations improve patient's quality of life by minimizing problems and increasing the device's lifespan by enabling the market to grow at a CAGR of 13.92% from 2026 to 2032.

Artificial Heart Market: Definition/ Overview

An artificial heart is a mechanical device that replaces a failing human heart, either temporarily or permanently, to keep blood flowing and oxygen delivered to the body. It is primarily used in individuals with severe heart diseases including as end-stage heart failure in which the heart is no longer able to efficiently pump blood. The artificial heart replicates the natural heart's function by pumping blood through the circulatory system ensuring that essential organs receive the oxygen and nutrition they require to function.

The artificial heart is a groundbreaking medical device that replaces the function of a failing human heart providing life-saving support to patients suffering from serious cardiac diseases. One of the key uses for artificial hearts is as a bridge to heart transplantation. An artificial heart can temporarily replace the failing organ in individuals with end-stage heart failure in which the heart can no longer adequately pump blood. This enables patients to survive while awaiting a donor heart for transplantation.

The future usage of mechanical hearts has the potential to change cardiology providing new hope to patients with serious cardiac diseases. As the global burden of heart disease rises, artificial hearts are becoming an increasingly important option for patients who are unable to receive heart transplants due to a lack of donor organs or other medical reasons. These devices are designed to perform similarly to a natural heart moving

blood throughout the body and prolonging life when the patient's own heart is no longer functioning.

Will the Rising Incidence of Cardiovascular Diseases Drive the Artificial Heart Market?

The increasing incidence of cardiovascular diseases (CVDs) is a major driver of the artificial heart market. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of mortality worldwide, killing an estimated 17.9 million people each year. This accounts for 31% of all deaths globally. CVD prevalence has continuously increased, particularly in low- and middle-income nations which account for more than 75% of CVD deaths. In the United States alone, the Centers for Disease Control and Prevention (CDC) says that heart disease is the leading cause of death accounting for around 655,000 fatalities yearly or one in every four deaths.

This worrying rise in CVD prevalence is predicted to increase demand for artificial hearts as a life-saving treatment for individuals with end-stage heart failure. The National Heart, Lung, and Blood Institute (NHLBI) estimates that roughly 6.2 million adults in the United States have heart failure with projections indicating that this figure could rise to over 8 million by 2030. Furthermore, the United Network for Organ Sharing (UNOS) reports that as of 2021, there were over 3,500 people on the waiting list for a heart transplant in the United States. Given the ongoing paucity of donor hearts, artificial hearts serve as an important bridge-to-transplant option or, in certain situations, a destination therapy.

Will the High-Cost Hamper the Artificial Heart Market?

The high cost of artificial hearts poses a substantial barrier to market expansion, potentially limiting adoption and accessibility. According to the National Institute of Health (NIH), the overall cost of an artificial heart transplant including the device and related medical care can range between $150,000 and $500,000. Many patients and healthcare systems, particularly in developing countries or locations with low healthcare resources are unable to afford mechanical hearts due to the significant financial load. According to the Centers for Medicare and Medicaid Services (CMS), while they cover certain ventricular assist devices (VADs) for qualifying beneficiaries, full artificial heart transplants are not usually reimbursed, further limiting access for elderly patients who frequently require such operations.

The high cost has an impact not just on patient access but also on research and development in the sector. The Food and Drug Administration (FDA) has claimed that the long clinical trials required for artificial heart approval can cost manufacturers hundreds of millions of dollars discouraging some companies from joining the market or developing novel designs. This expensive barrier to entry may stifle technological developments and hinder competition, thus maintaining high costs in the long run. Furthermore, the National Heart, Lung, and Blood Institute (NHLBI) has stated that, while government funding for artificial heart research has increased in recent years, it remains insufficient to encourage rapid innovation and cost reduction in the sector.

Category-Wise Acumens

Will Broader Application and Widespread Adoption Drive Growth in the Type Segment?

Left Ventricular Assist Devices (LVADs) are in a dominant position owing to their broad application and widespread adoption in treating patients with severe heart failure. LVADs are intended to support the left ventricle, the heart's major pumping chamber responsible for delivering oxygen-rich blood to the body. These devices are frequently utilized as a bridge to heart transplantation providing critical-care patients with the essential assistance while they wait for a donor heart. Furthermore, LVADs are increasingly being used as destination therapy for patients who are not candidates for transplantation due to age, comorbidities, or other criteria.

The incidence of heart failure, particularly among the elderly has contributed to the demand for LVADs. As the world's population ages, the prevalence of heart failure is predicted to climb creating a higher demand for advanced treatments such as LVADs. Furthermore, technological advances in LVAD design have resulted in smaller, more efficient, and easier-to-implant devices lowering surgical risks while increasing patient outcomes. Wireless power transfer and better biocompatible materials have improved the safety and endurance of LVADs making them more appealing to patients and healthcare professionals.

Will the Ongoing Research and Development Drive the Technology Segment?

Continuous flow technology has emerged as the dominant force, owing to major improvements over prior pulsatile flow systems. Continuous flow artificial hearts use a continuous, non-pulsatile mechanism to pump blood throughout the body providing several significant benefits that make them the favored choice in the medical profession. One of the key advantages is their tiny size which enables easier implantation in a broader range of patients including those with lower body proportions. This downsizing has made the technology more accessible and minimally intrusive resulting in better patient outcomes and shorter recovery periods.

Furthermore, continuous flow devices are noted for their long lifespan. Because they work on a consistent, continuous basis without the need for moving elements to contract and expand like normal heartbeats, Continuous flow technology not only leads the artificial heart market but it also symbolizes the future of cardiac support systems. Continuous research and development in this area improves the performance and reliability of these devices, further distinguishing them from their pulsatile predecessors. The medical community's choice of continuous flow devices is also influenced by the larger trend toward minimally invasive and long-lasting cardiac care solutions. This trend is likely to continue as technology advances ensuring that continuous flow artificial hearts stay at the forefront of life-saving cardiac procedures.

Country/Region-wise Acumens

Will Advanced Healthcare Infrastructure Drive the Market in the North American Region?

The North American region, particularly the United States and Canada is well-positioned to dominate the artificial heart industry due to its advanced healthcare infrastructure and significant investments in medical technology. North America, notably the United States, has some of the world's most complex healthcare systems with cutting-edge medical facilities, robust research and development skills, and significant investment in healthcare technology. These variables work together to produce an atmosphere that encourages the acceptance and development of advanced medical equipment such as artificial hearts.

The North American market benefits from an established regulatory structure that facilitates the approval and marketing of breakthrough medical innovations. The US Food and Drug Administration (FDA) is an important player in this process ensuring that new medical devices fulfill high safety and efficacy requirements before they are released to the market. This stringent approval process, though difficult, ultimately contributes to the trust and confidence that healthcare providers and patients have in these devices. The availability of significant funding and payment options for sophisticated cardiac treatments makes artificial hearts more accessible to patients, which drives market growth. Furthermore, the region's aging population, which is increasingly susceptible to heart-related ailments raises the need for effective cardiac support systems.

Will the Demand for Advanced Cardiac Therapies Drive the Market in the Asia Pacific Region?

The Asia Pacific region is expected to be the fastest-growing artificial heart market owing to increased cardiovascular disease prevalence and healthcare expenditure. This rapid expansion is primarily attributable to the vast population base, improved healthcare infrastructure, and increased awareness of innovative cardiac therapy in nations such as China, Japan, and India.

The demand for innovative cardiac therapy in Asia Pacific is projected to drive the artificial heart industry. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of mortality worldwide claiming an estimated 17.9 million lives per year. In the Western Pacific region which includes many Asian countries, cardiovascular diseases account for 35% of all deaths.

The increased frequency of CVD combined with an aging population is driving significant demand for sophisticated cardiac treatments including artificial hearts. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), Asia and the Pacific's elder population is predicted to grow from 630 million in 2020 to approximately 1.3 billion by 2050. This demographic transition is projected to increase the incidence of heart failure, and thus the demand for artificial hearts. Furthermore, increased healthcare spending in the region is encouraging the use of modern medical technologies.

Competitive Landscape

The Artificial Heart Market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the artificial heart market include:

• Jarvik Heart, Inc.
• BiVACOR, Inc.
• CARMAT SA
• SynCardia Systems, LLC
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

Latest Developments

• In September 2023, Abbott (NYSE: ABT) announced the completion of its acquisition of Bigfoot Biomedical, a market leader in the creation of smart insulin control devices for diabetics.

Artificial Heart Market, By Category

• Type:
• Total Artificial Hearts (TAH)
• Left Ventricular Assist Devices (LVAD)
• Technology:
• Continuous Flow Technology
• Pulsatile Flow Technology
• End-User:
• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. INTRODUCTION

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Artificial Heart Market, By Type

• Total Artificial Hearts (TAH)
• Left Ventricular Assist Devices (LVAD)

5. Artificial Heart Market, By Technology

• Continuous Flow Technology
• Pulsatile Flow Technology

6. Artificial Heart Market, By End-User

• Hospitals
• Ambulatory Surgical Centers (ASCs)

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• SynCardia Systems, LLC
• Carmat
• Abiomed
• CryoLife, Inc.
• ReinHeart TAH GmbH
• Jarvik Heart, Inc.
• Calon Cardio-Technology Ltd.
• BiVACOR, Inc.
• CARMAT SA
• MyLVAD
• Thoratec Corporation
• Cirtec
• Abbott
• ON-X LIFE TECHNOLOGIES, INC.
• ABIOMED
• Cleveland Heart, Inc.
• Tianjin Medical
• Braile Biomedica
• Edwards Lifesciences
• R. Bard, Inc.
• Terumo Corporation
• MAQUET GmbH & Co. KG
• Sorin Group
• Medtronic, Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References